FIELD: biotechnology.
SUBSTANCE: invention relates to antitumor tetraspecific antibodies, and can be used in medicine for the treatment of a subject with a CD19-positive malignant neoplasm. The following was constructed: a recombinant tetraspecific antibody with specificity for binding to CD3, CD19, PD-L1 and 4-1BB containing the following in tandem from the N-terminus to the C-terminus: a binding domain for CD-3, a binding domain for CD19, an IgG Fc domain, a binding domain for PD-L1, and a binding domain for 4-1BB, wherein the binding domain for tumor-associated antigen is not adjacent to the binding domain for T-cell costimulatory receptor.
EFFECT: invention provides an antitumor agent having activity in redirecting PBMC T-cell activity and stimulating the proliferation of CD8 T-cells against an acute B lymphoblastic leukemia cell line.
5 cl, 23 dwg, 11 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF PRODUCING AND USING GUIDE AND NAVIGATION CONTROL PROTEINS | 2019 |
|
RU2824896C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
